Literature DB >> 9276076

In vitro 1H-magnetic resonance spectroscopy of postmortem brains with schizophrenia.

M Omori1, J Pearce, R A Komoroski, W S Griffin, R E Mrak, M M Husain, C N Karson.   

Abstract

Some evidence suggests that thalamic dysfunction could explain some of the signs and symptoms of schizophrenia. We measured the absolute concentrations of amino acid metabolites in thalamus, frontal pole, and cerebellar vermis in extracts of postmortem brains from 8 schizophrenics and 10 controls using high-resolution 1H-magnetic resonance spectroscopy. The concentrations of N-acetyl aspartate, glutamate, and valine tended to be reduced in the thalamus of the schizophrenic group. Although it is difficult to ascribe significance to the "tendencies," these data may tend to support other data suggesting decreased thalamic volume or neuronal number in schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9276076     DOI: 10.1016/S0006-3223(96)00409-X

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  10 in total

Review 1.  Recent advances in targeting the ionotropic glutamate receptors in treating schizophrenia.

Authors:  Robert E McCullumsmith; John Hammond; Adam Funk; James H Meador-Woodruff
Journal:  Curr Pharm Biotechnol       Date:  2012-06       Impact factor: 2.837

Review 2.  Testing models of thalamic dysfunction in schizophrenia using neuroimaging.

Authors:  K Sim; T Cullen; D Ongur; S Heckers
Journal:  J Neural Transm (Vienna)       Date:  2005-10-27       Impact factor: 3.575

3.  Proton magnetic resonance spectroscopy of the anterior cingulate gyrus, insular cortex and thalamus in schizophrenia associated with idiopathic unconjugated hyperbilirubinemia (Gilbert's syndrome).

Authors:  Rei Yasukawa; Tsuyoshi Miyaoka; Shoichi Mizuno; Takuji Inagaki; Jun Horiguchi; Kazushige Oda; Hajime Kitagaki
Journal:  J Psychiatry Neurosci       Date:  2005-11       Impact factor: 6.186

4.  Abnormal expression of glutamate transporter and transporter interacting molecules in prefrontal cortex in elderly patients with schizophrenia.

Authors:  Deborah Bauer; Daya Gupta; Vahram Harotunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Schizophr Res       Date:  2008-08-03       Impact factor: 4.939

5.  Proton magnetic resonance spectroscopy (1H-MRS) of the cerebellum in men with schizophrenia.

Authors:  P Tibbo; C C Hanstock; S Asghar; P Silverstone; P S Allen
Journal:  J Psychiatry Neurosci       Date:  2000-11       Impact factor: 6.186

6.  Proton magnetic resonance spectroscopy (H-MRS) in chronic schizophrenia. A single-voxel study in three regions involved in a pathogenetic theory.

Authors:  F Granata; G Pandolfo; S Vinci; C Alafaci; N Settineri; R Morabito; A Pitrone; M Longo
Journal:  Neuroradiol J       Date:  2013-07-16

7.  Evidence of widespread metabolite abnormalities in Myalgic encephalomyelitis/chronic fatigue syndrome: assessment with whole-brain magnetic resonance spectroscopy.

Authors:  Christina Mueller; Joanne C Lin; Sulaiman Sheriff; Andrew A Maudsley; Jarred W Younger
Journal:  Brain Imaging Behav       Date:  2020-04       Impact factor: 3.978

8.  Glutamatergic gene expression is specifically reduced in thalamocortical projecting relay neurons in schizophrenia.

Authors:  Monsheel S Sodhi; Micah Simmons; Robert McCullumsmith; Vahram Haroutunian; James H Meador-Woodruff
Journal:  Biol Psychiatry       Date:  2011-05-06       Impact factor: 13.382

9.  Metabolic abnormalities in fronto-striatal-thalamic white matter tracts in schizophrenia.

Authors:  Clare L Beasley; Andrew J Dwork; Gorazd Rosoklija; J John Mann; Branislav Mancevski; Zlatko Jakovski; Natasa Davceva; Andrew R Tait; Suzana K Straus; William G Honer
Journal:  Schizophr Res       Date:  2009-03-09       Impact factor: 4.939

10.  Phospholipid composition of postmortem schizophrenic brain by 31P NMR spectroscopy.

Authors:  John M Pearce; Richard A Komoroski; Robert E Mrak
Journal:  Magn Reson Med       Date:  2009-01       Impact factor: 4.668

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.